Hello again it’s me Dr Candice Johnson. The E&L conference took place on May 17th – 18th and it was so nice meeting colleagues and hearing about all the developments in the E&L field. The E&L community is eagerly anticipating the changes that the ISO-10993-17 standard and the ICH Q3E guideline will bring. Several presentations …
Continue reading “Extractables and Leachables (E&L) USA 2023 Conference”
Instem will be starting a read-across collaborative working group.
Dr Brenda Finney discusses the possibility of utilising all of your existing and new data for effective drug discovery and development.
(Q) SAR and veterinary medical products
Instem’s In Silico summary for SOT 2023.
Guest Author Dr Frances Hall highlights the risks with the augmented intelligence approach when providing a safety review for PLK4.
At this year’s SOT in Nashville (March 19-23, 2023), Instem will be organizing two workshops related to cancer assessments.1 In the first workshop, to be held on Tuesday, March 21, 4:30 PM – 5:30 PM (CT) in Room 101B, we will discuss carcinogenicity assessments aligned with the ICH S1B guideline2, specifically focusing on the weight …
Instem will again have a large presence at this year’s Society of Toxicology meeting in Nashville.1 As part of the scientific program, we will be co-authoring on nine posters covering the spectrum of scientific topics where we are undertaking research and development activities. This work supports many regulatory mandates and guidelines, including SEND, carcinogenicity risk …
Continue reading “Nine Instem Posters at the 2023 SOT Meeting”
The eTRANSAFE project1 is a strategically important project that has been developing a translational technology infrastructure to support drug safety assessments. The project started around 5 years ago and has been jointly funded by the European Innovative Medicines Initiative alongside the pharmaceutical industry. The partners on the project include representatives from the pharmaceutical industry, academia, …
Continue reading “Final meeting of the current eTRANSAFE consortium”
The U.S. Congress recently passed the FDA Modernization Act 2.01 which permits the use of alternatives to animal studies as part of the FDA’s regulatory approval process. The new legislation explicitly identifies in silico models as one of these alternatives. This legislation is an important step forward in the use of alternative methods and will …
